PHC Holdings Corp. (6523) AI Stock Analysis

• Market Cap: €131.79B
• Dividend Yield: 4.07%
• Average Volume (3M): 164.09K
• Price to Earnings (P/E): 11.6
• Beta (1Y): 0.55
• Revenue Growth: 0.70%
• EPS Growth: N/A
• Country: JP
• Employees: 9,245
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -18.55
• Shares Outstanding: 126,721,820
• 10 Day Avg. Volume: 194,380
• 30 Day Avg. Volume: 164,093
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1,154.80
• Price Target Upside: 11.90% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 54 Neutral
• Price Target: ¥993.00 ▼(-3.78% Downside)

PHC Holdings Corp. has a moderate overall stock score of 54. The company's financial performance is challenged by declining revenue and high leverage, which are significant risk factors. However, the stock's valuation is attractive with a low P/E ratio and a high dividend yield, providing potential upside. Technical indicators suggest a bearish trend, but the oversold condition could lead to a rebound.

PHC Holdings Corp. Business Overview & Revenue Model

Company Description

PHC Holdings Corp. (6523) is a leading healthcare company based in Japan, primarily focused on the development, manufacturing, and marketing of medical devices, pharmaceuticals, and healthcare-related products. The company operates in various sectors, including diagnostics, medical instruments, and healthcare IT solutions, aiming to enhance patient care and improve healthcare outcomes through innovative technology and comprehensive healthcare solutions.

How the Company Makes Money

PHC Holdings Corp. generates revenue through multiple key streams, primarily from the sale of medical devices and diagnostic products. The company offers a range of products including blood glucose monitoring systems, automated clinical analyzers, and other medical supplies that cater to hospitals, clinics, and healthcare providers. Additionally, PHC Holdings engages in research and development partnerships with other healthcare organizations, which not only enhances its product offerings but also contributes to revenue through collaborative projects and licensing agreements. The company's strategic focus on expanding its presence in emerging markets and investing in cutting-edge technology further drives its earnings, allowing it to tap into new customer segments and increase market share.

PHC Holdings Corp. Financial Statement Overview

Summary

PHC Holdings Corp. faces challenges with declining revenue and profitability pressures, as evidenced by the negative revenue growth and low net profit margin. The balance sheet shows high leverage, which could be a risk factor, but the company maintains a moderate return on equity. Cash flow generation is improving, providing some financial flexibility. The company needs to focus on revenue growth and debt management to enhance its financial health.

Income Statement

PHC Holdings Corp. has shown a decline in revenue with a negative growth rate of -36.8% in the TTM period, indicating significant challenges in maintaining sales momentum. The gross profit margin stands at 45.97%, which is relatively healthy, but the net profit margin is low at 2.90%, reflecting limited profitability. The EBIT and EBITDA margins are moderate at 6.68% and 14.39%, respectively, suggesting some operational efficiency but room for improvement.

Balance Sheet

The company's debt-to-equity ratio is high at 1.80, indicating a significant reliance on debt financing, which could pose financial risks. Return on equity is modest at 7.45%, showing moderate efficiency in generating returns from equity. The equity ratio is approximately 26.54%, suggesting a balanced but slightly leveraged capital structure.

Cash Flow

PHC Holdings Corp. has demonstrated a positive free cash flow growth rate of 5.07% in the TTM period, indicating improved cash generation. The operating cash flow to net income ratio is 0.30, and the free cash flow to net income ratio is 0.72, reflecting a reasonable conversion of income into cash flow, though there is room for strengthening cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	360.26B	361.59B	353.90B	356.43B	340.45B	306.07B
Gross Profit	166.85B	166.22B	157.97B	169.13B	165.24B	143.65B
EBITDA	53.17B	52.33B	30.15B	36.76B	37.56B	62.29B
Net Income	11.32B	10.48B	-12.89B	-3.22B	-8.46B	16.91B
Balance Sheet
Total Assets	519.78B	532.48B	564.33B	561.57B	591.32B	569.02B
Cash, Cash Equivalents and Short-Term Investments	34.83B	39.59B	51.82B	63.25B	97.63B	63.96B
Total Debt	251.40B	255.26B	285.05B	292.62B	307.94B	321.55B
Total Liabilities	382.48B	391.31B	425.16B	422.74B	455.26B	461.46B
Stockholders Equity	137.90B	141.64B	139.51B	138.01B	135.37B	107.02B
Cash Flow
Free Cash Flow	31.87B	30.33B	26.67B	9.86B	39.32B	35.70B
Operating Cash Flow	42.11B	41.94B	41.30B	21.38B	51.05B	47.85B
Investing Cash Flow	-7.30B	-8.47B	-21.07B	-17.52B	-12.52B	-16.31B
Financing Cash Flow	-37.22B	-39.07B	-39.14B	-40.83B	-7.01B	-20.39B

PHC Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1032.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6523, the sentiment is Positive. The current price of 1032 is above the 20-day moving average (MA) of 1012.70, above the 50-day MA of 1008.73, and above the 200-day MA of 961.85, indicating a bullish trend. The MACD of 16.04 indicates Negative momentum. The RSI at 54.86 is Neutral, neither overbought nor oversold. The STOCH value of 53.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6523.

PHC Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6678	―	¥16.16B	15.75	―	3.63%	-8.07%	-38.21%
6849	―	¥289.73B	21.12	―	1.82%	4.43%	-1.39%
6823	―	¥31.04B	10.51	―	2.78%	7.99%	28.81%
4549	―	¥74.45B	34.68	―	2.38%	3.80%	6.68%
7600	―	¥13.54B	―	―	2.92%	4.84%	-148.94%
6523	―	€131.79B	11.59	8.31%	4.07%	0.70%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%